Sapna R. Srivastava

Dr. Sapna R.
Srivastava is an Independent Director at Alumis, Inc., an Independent Director at Nuvalent, Inc., an Independent Non-Executive Director at Aura Biosciences, Inc., an Independent Director at SQZ Biotechnologies Co. and a Strategic Advisor at BioPlus Acquisition Corp.
She is on the Board of Directors at Alumis, Inc., Nuvalent, Inc., Aura Biosciences, Inc., SQZ Biotechnologies Co., AsclepiX Therapeutics LLC and Trickle Up Program, Inc. Dr. Srivastava was previously employed as an Independent Director by Tourmaline Bio, Inc., an Independent Director by Innoviva, Inc., an Independent Director by Social Capital Suvretta Holdings Corp.
II, a Chief Financial Officer by eGenesis, Inc., an Independent Director by Talaris Therapeutics, Inc., a Chief Financial & Strategy Officer by Abide Therapeutics, Inc., a Chief Financial & Strategy Officer by Intellia Therapeutics, Inc., an Independent Director by MYOS Corp., an Analyst by Goldman Sachs & Co., an Analyst by Thomas Weisel Partners LLC, an Associate by JP Morgan Direct Corporate Finance, and a Research Analyst by Morgan Stanley & Co., Inc. She also served on the board at VelosBio, Inc. She received her undergraduate degree from St. Xavier's College (Mumbai) and a doctorate degree from New York University School of Medicine.